ThermoGenesis Holdings, Inc. (THMO)

OTC • Currency in USD

$0.00

0.00%

Last Update: 3 Sept 2025, 00:00

$1.59K

Market Cap

0.00

P/E Ratio (TTM)

—

Forward Dividend Yield

$0.00 - $0.30

52 Week Range

THMO Stock Price Chart

Explore ThermoGenesis Holdings, Inc. interactive price chart. Choose custom timeframes to analyze THMO price movements and trends.

THMO Company Profile

Discover essential business fundamentals and corporate details for ThermoGenesis Holdings, Inc. (THMO) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Medical - Devices

IPO Date

5 Jun 1987

Employees

25.00

Website

https://www.thermogenesis.com

CEO

Xiaochun Xu

Description

ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics in the United States, China, the United Arab Emirates, Vietnam, and internationally. The company provides medical device products for automated cell processing. Its clinical bio-banking applications include AXP II Automated Cell Separation System, an automated fully closed cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. The company's point-of-care applications include XP Point-of-Care System, an automated, fully closed, sterile system that allows for the rapid and automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; and PXP-1000 System, an automated, fully closed system that provides fast, reproducible separation of multiple cellular components from blood with minimal red blood cell contamination. Its cell processing products comprise X-Series products for general laboratory use, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The company also provides contract development and manufacturing services for cell and cell-based gene therapies. It markets and sells its medical device products through independent distributors, as well as direct to end-user customers. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.

THMO Financial Timeline

Browse a chronological timeline of ThermoGenesis Holdings, Inc. corporate events including earnings releases, dividend announcements, and stock splits.

Earnings released on 11 Jun 2025

Earnings released on 6 Jan 2025

Earnings released on 30 Dec 2024

Earnings released on 26 Sept 2024

Earnings released on 15 Apr 2024

EPS came in at -$2.33 falling short of the estimated -$0.02 by -14.60K%, while revenue for the quarter reached $2.74M , missing expectations by -27.97%.

Earnings released on 28 Mar 2024

EPS came in at -$1.94 falling short of the estimated -$0.01 by -19.29K%, while revenue for the quarter reached $2.41M , missing expectations by -32.23%.

Earnings released on 13 Nov 2023

EPS came in at -$1.44 falling short of the estimated -$0.21 by -585.71%, while revenue for the quarter reached $2.19M , missing expectations by -38.20%.

Earnings released on 10 Aug 2023

EPS came in at -$0.91 falling short of the estimated -$0.01 by -9.20K%, while revenue for the quarter reached $2.27M , missing expectations by -50.59%.

Earnings released on 15 May 2023

EPS came in at -$3.88 falling short of the estimated -$0.31 by -1.15K%, while revenue for the quarter reached $2.57M , missing expectations by -3.89%.

Earnings released on 30 Mar 2023

EPS came in at $0.25 surpassing the estimated -$0.90 by +127.78%, while revenue for the quarter reached $10.48M , beating expectations by +262.73%.

Stock split effective on 22 Dec 2022

Shares were split 1 : 45 , changing the number of shares outstanding and the price per share accordingly.

Earnings released on 10 Nov 2022

EPS came in at -$4.50 falling short of the estimated -$1.35 by -233.33%, while revenue for the quarter reached $2.12M , missing expectations by -29.50%.

Earnings released on 11 Aug 2022

EPS came in at -$9.01 falling short of the estimated $0.90 by -1.10K%, while revenue for the quarter reached $3.03M , missing expectations by -47.78%.

Earnings released on 19 May 2022

EPS came in at -$7.21 falling short of the estimated $0.90 by -901.11%, while revenue for the quarter reached $2.66M , missing expectations by -52.45%.

Earnings released on 28 Mar 2022

EPS came in at -$9.91 falling short of the estimated -$2.70 by -267.04%, while revenue for the quarter reached $2.42M , missing expectations by -28.88%.

Earnings released on 12 Nov 2021

EPS came in at -$6.76 falling short of the estimated -$3.60 by -87.78%, while revenue for the quarter reached $3.16M , beating expectations by +43.66%.

Earnings released on 12 Aug 2021

EPS came in at -$17.12 falling short of the estimated -$8.11 by -111.10%, while revenue for the quarter reached $2.20M , beating expectations by +7.74%.

Earnings released on 13 May 2021

EPS came in at -$9.46 falling short of the estimated -$5.86 by -61.43%, while revenue for the quarter reached $1.52M , missing expectations by -42.97%.

Earnings released on 17 Mar 2021

EPS came in at -$10.81 , while revenue for the quarter reached $1.95M .

Earnings released on 12 Nov 2020

EPS came in at -$16.67 falling short of the estimated -$4.50 by -270.44%, while revenue for the quarter reached $2.36M .

THMO Stock Performance

Access detailed THMO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.